Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy | |
Huang, Ou2; Jiang, Min2; Zhang, Xi2; Xie, Zuoquan1![]() ![]() | |
刊名 | JAPANESE JOURNAL OF CLINICAL ONCOLOGY
![]() |
2013-11 | |
卷号 | 43期号:11页码:1064-1072 |
关键词 | grb14 breast cancer locally advanced neoadjuvant chemotherapy prognosis |
ISSN号 | 0368-2811 |
DOI | 10.1093/jjco/hyt130 |
文献子类 | Article |
英文摘要 | Objective: Growth factor receptor-binding protein 14, a new member of noncatalytic adaptor proteins family, has been shown to be upregulated in breast cancer. We investigated the prognostic value of growth factor receptor-binding protein 14 expression in breast cancer patients treated with neoadjuvant chemotherapy. Methods: Primary breast cancer specimens were taken from locally advanced breast cancer patients in a Phase II clinical trial of neoadjuvant chemotherapy and the expression pattern of growth factor receptor-binding protein 14 was determined by immunohistochemistry. Kaplan-Meier analysis and Cox regression model were used to assess disease-free and overall survival, according to the expression of growth factor receptor-binding protein 14 in tumor cells. Results: Our result showed that growth factor receptor-binding protein 14 was highly expressed in 23.1% of breast cancer sections, and high expression of growth factor receptor-binding protein 14 was significantly associated with better disease-free (P = 0.016, hazard ratio 0.07, 95% confidence interval 0.06-0.08) and overall survival (P = 0.004, hazard ratio 0.02, 95% confidence interval 0.02-0.03), compared with the low-expression group. Multivariate analysis indicated that high expression of growth factor receptor-binding protein 14 was an independent good prognostic factor for both disease-free (P = 0.04, hazard ratio 0.37, 95% confidence interval 0.14-0.98) and overall survival (P = 0.03, hazard ratio 0.11, 95% confidence interval 0.10-0.82). Conclusions: High expression of growth factor receptor-binding protein 14 in breast cancer cells may help to identify low-risk patients for additional therapies after neoadjuvant chemotherapy. |
资助项目 | National Natural Science Foundation of China[81202087] ; National Natural Science Foundation of China[81172520] ; National Natural Science Foundation of China[81202088] ; Leading Academic Discipline Project of Shanghai Municipal Education Commission[J50208] ; Shanghai Science and Technology Committee[12ZR1446400] ; Shanghai Science and Technology Committee[12140901503] ; Shanghai Charity Cancer Research Center[00000000] |
WOS关键词 | ADAPTER PROTEIN GRB14 ; RECEPTOR ; EXPRESSION ; MICROARRAY ; MODULATOR ; INSULIN ; FAMILY ; RISK |
WOS研究方向 | Oncology |
语种 | 英语 |
出版者 | OXFORD UNIV PRESS |
WOS记录号 | WOS:000326647400002 |
内容类型 | 期刊论文 |
源URL | [http://119.78.100.183/handle/2S10ELR8/277401] ![]() |
专题 | 药理学第一研究室 |
通讯作者 | Shen, Kunwei |
作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai 200031, Peoples R China 2.Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Surg, Shanghai 200025, Peoples R China; |
推荐引用方式 GB/T 7714 | Huang, Ou,Jiang, Min,Zhang, Xi,et al. Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY,2013,43(11):1064-1072. |
APA | Huang, Ou.,Jiang, Min.,Zhang, Xi.,Xie, Zuoquan.,Chen, Xiaosong.,...&Shen, Kunwei.(2013).Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.JAPANESE JOURNAL OF CLINICAL ONCOLOGY,43(11),1064-1072. |
MLA | Huang, Ou,et al."Grb14 as an Independent Good Prognosis Factor for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy".JAPANESE JOURNAL OF CLINICAL ONCOLOGY 43.11(2013):1064-1072. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论